abrdn Life Sciences Investors (NYSE:HQL) Stock Price Up 2.5% - Still a Buy?

Key Points

• abrdn Life Sciences Investors raised its quarterly dividend to $0.56 (from $0.50), implying a $2.24 annualized payment and a roughly 13.8% yield; the ex-dividend date is Feb 20 and the dividend is payable Mar 31.
• Shares traded up about 2.5% to $16.26 on Monday (from $15.87) with mid-day volume of ~112,213 shares, roughly 10% below its average daily volume.
• HQL is a closed-end life sciences fund focused on biotech, pharmaceuticals and medical devices, and institutional investors own about 32.21% of the stock.

abrdn Life Sciences Investors (NYSE:HQL - Get Free Report)'s share price rose 2.5% on Monday . The stock traded as high as $16.36 and last traded at $16.2610. Approximately 112,213 shares traded hands during mid-day trading, a decline of 10% from the average daily volume of 125,229 shares. The stock had previously closed at $15.87.

abrdn Life Sciences Investors Trading Up 2.5%

The business has a fifty day moving average price of $16.81 and a two-hundred day moving average price of $16.30.

abrdn Life Sciences Investors Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Friday, February 20th will be paid a dividend of $0.56 per share. This represents a $2.24 annualized dividend and a yield of 13.8%. This is a boost from abrdn Life Sciences Investors's previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Friday, February 20th.

Institutional Trading of abrdn Life Sciences Investors

Several institutional investors have recently added to or reduced their stakes in HQL. Geneos Wealth Management Inc. boosted its position in shares of abrdn Life Sciences Investors by 200.1% during the second quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company's stock worth $29,000 after buying an additional 1,529 shares during the period. Global Retirement Partners LLC raised its holdings in shares of abrdn Life Sciences Investors by 187.8% in the 4th quarter. Global Retirement Partners LLC now owns 7,039 shares of the company's stock valued at $118,000 after buying an additional 4,593 shares during the period. Mercer Global Advisors Inc. ADV purchased a new stake in shares of abrdn Life Sciences Investors in the 4th quarter valued at $177,000. Cornerstone Advisors LLC acquired a new position in abrdn Life Sciences Investors during the 3rd quarter worth about $175,000. Finally, Evolve Private Wealth LLC purchased a new position in abrdn Life Sciences Investors during the 4th quarter valued at about $199,000. Institutional investors and hedge funds own 32.21% of the company's stock.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors NYSE: HQL is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.